Noncardiovascular deaths are more common than cardiovascular deaths in patients with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial

American Heart Journal

Volumn 186, Issue , 2017, Pages 73-82

  Sharma, Abhinav ^a,b   de Souza Brito, Flávio ^a   Sun, Jie Lena ^a   Thomas, Laine ^a   Haffner, Steven ^c   Holman, Rury R ^d   Lopes, Renato D ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NATEGLINIDE; POTASSIUM; VALSARTAN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NON MELANOMA SKIN CANCER; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; SUDDEN CARDIAC DEATH; AGED; COMPLICATION; GLUCOSE INTOLERANCE; MIDDLE AGED; MORTALITY; RISK FACTOR;

AGED; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; FEMALE; FOLLOW-UP STUDIES; GLUCOSE INTOLERANCE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 85012236107     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2016.12.011     Document Type: Article

References (22)

1. 1. Coutinho, M., Gerstein, H.C., Wang, Y., et al. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22 (1999), 233–240.
2. 2. Grundy, S.M., Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol 59 (2012), 635–643.
3. 3. Ford, E.S., Zhao, G., Li, C., Pre-diabetes and the risk for cardiovascular disease. J Am Coll Cardiol 55 (2010), 1310–1317.
4. 4. Campbell, P.T., Newton, C.C., Patel, A.V., et al. Diabetes and cause-specific mortality in a prospective cohort of one million US adults. Diabetes Care 35 (2012), 1835–1844.
5. 5. Coughlin, S.S., Calle, E.E., Teras, L.R., et al. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159 (2004), 1160–1167.
6. 6. Bertoni, A.G., Saydah, S., Brancati, F.L., Diabetes and the risk of infection-related mortality in the U.S. Diabetes Care 24 (2001), 1044–1049.
7. 7. Califf, R.M., Boolell, M., Haffner, S.M., et al. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial. Am Heart J 156 (2008), 623–632.
8. 8. NAVIGATOR Study Group, McMurray, J.J., Holman, R.R., et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 362 (2010), 1477–1490.
9. 9. Spranger, J., Kroke, A., Möhlig, M., et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)–Potsdam Study. Diabetes 52 (2003), 812–817.
10. 10. Barr, E.L., Zimmet, P.Z., Welborn, T.A., et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 116 (2007), 151–157.
11. 11. Saydah, S.H., Loria, C.M., Eberhardt, M.S., et al. Abnormal glucose tolerance and the risk of cancer death in the United States. Am J Epidemiol 157 (2003), 1092–1100.
12. 12. Emerging Risk Factors Collaboration, Seshasai, S.R.K., Kaptoge, S., et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364 (2011), 829–841.
13. 13. Arcidiacono, B., Iiritano, S., Nocera, A., et al. Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp Diabetes Res, 2012, 2012, 789174.
14. 14. Giovannucci, E., Harlan, D.M., Archer, M.C., et al. Diabetes and cancer: a consensus report. Diabetes Care 33 (2010), 1674–1685.
15. 15. Khandwala, H.M., McCutcheon, I.E., Flyvbjerg, A., et al. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21 (2000), 215–244.
16. 16. Preiss, D., Thomas, L.E., Sun, J.L., et al. Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial. BMJ Open, 2, 2012 [pii: e001925].
17. 17. van der Bom, J.G., Heckbert, S.R., Lumley, T., et al. Platelet count and the risk for thrombosis and death in the elderly. J Thromb Haemost 7 (2009), 399–405.
18. 18. Rees, J.R., Zens, M.S., Gui, J., et al. Non melanoma skin cancer and subsequent cancer risk. PLoS One, 9, 2014, e99674.
19. 19. Erlinger, T.P., Muntner, P., Helzlsouer, K.J., WBC count and the risk of cancer mortality in a national sample of U.S. adults: results from the Second National Health and Nutrition Examination Survey mortality study. Cancer Epidemiol Biomarkers Prev 13 (2004), 1052–1056.
20. 20. Shankar, A., Wang, J.J., Rochtchina, E., et al. Association between circulating white blood cell count and cancer mortality: a population-based cohort study. Arch Intern Med 166 (2006), 188–194.
21. 21. Wannamethee, S.G., Lever, A.F., Shaper, A.G., et al. Serum potassium, cigarette smoking, and mortality in middle-aged men. Am J Peidemiol 145 (1997), 598–606.
22. 22. Bangalore, S., Kumar, S., Kjeldsen, S.E., et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol 12 (2011), 65–82.